{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.13659","value":"20.22090"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"141"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.53852","value":"74.9750"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"}],"units":"Participants"}],"title":"Cycle 2 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"141"}],"units":"Participants"}],"description":"%BAUEC0-4 is the percent inhibition for AUEC0-4. Crossover C1D1 and crossover C2D1 visits were combined with C1D1 and C2D1 visits, respectively for the analysis of this endpoint.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received AG-120 500 mg, tablet, orally, QD in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up, or the sponsor ended the study. Participants who experienced disease progression and received placebo were allowed to cross over to receive AG-120 500 mg, tablet, orally, QD in each 28-day treatment cycle.","id":"OG000","title":"Randomization Phase AG-120 Plus Cross Over Phase AG-120"}],"paramType":"MEAN","populationDescription":"PD Analysis Population consisted of all participants who were enrolled and received any dose of study medication (AG-120) with sufficient plasma sample data to assess pharmacodynamic parameters. Number analyzed is the number of participants with data available for analyses at the specified time point.","reportingStatus":"POSTED","timeFrame":"Post-dose Cycle 1 Day 1 and Cycle 2 Day 1 (each cycle = 28 days)","title":"Plasma 2-hydroxyglutarate (2-HG) Levels of AG-120: %BAUEC0-4","type":"SECONDARY","unitOfMeasure":"percent"}